journal article·2022-07

Amino acids and doxorubicin as building blocks for metal ion‐driven self‐assembly of biodegradable polyprodrugs for tumor theranostics

Daquan Wang, Ning Zhang, Tingting Yang, Yun Zhang, Xunan Jing, Yu Zhou, Jiangang Long, Lingjie Meng

Acta Biomaterialia· Volume 147
Publisher page

Abstract

On-demand designed theranostics nanoagents show promising applications for next-generation precision-and-personalized oncotherapy. Researchers have since aimed to develop nanoplatforms that can efficiently deliver drugs and contrast medium to tumor and release active ingredients in response to tumor microenvironment (TME) conditions. Herein, we propose a modular strategy, and develop a series of nanoplatforms based on metal-coordinated-polyprodrugs for cancer theranostics. The polyprodrugs were synthesized through a click-reaction between amino acid and doxorubicin (DOX) with dipropiolate. The backbones of the polyprodrugs had intrinsic sensitivities to pH and/or GSH, and provided abundant -COOH, -NH2, or -S-S- to chelate with functional metal ions and further self-assembled to form different morphologies. Dicysteine, which contains disulfide bond (-S-S-), was chosen to copolymerize with DOX and triethylene glycol dipropiolate (TEP) to prepare the pH/GSH dual-responsive polyprodrug poly(dicysteine-co-TEP-co-DOX) (pDTD), then separately coordinated with Gd3+, Fe3+, and Mn2+ to construct nanoplatforms pDTD@M (M representing the metal ions). In vitro and in vivo investigations suggest the metal-coordinated-polyprodrug nanoplatforms have good magnetic resonance imaging (MRI) ability and efficient tumor-growth inhibition with high safety. The design strategy of nanoplatforms based on metal-coordinated-polyprodrugs provides a new idea for on-demand construction of promising theranostics agents. STATEMENT OF SIGNIFICANCE: Compared to small molecule antitumor drugs, polymeric drugs have high drug loading ratio and are easily enriched at the tumor site to achieve improved therapy efficacy. This work utilizes click reactions to link amino acids with anticancer drugs to produce polymeric drugs that are degraded in response to tumor microenvironment and released small molecule antitumor drugs mainly in tumor sites, and subtly utilizes the coordination of amino acid to chelate MRI functional metal ion to realize enhanced MRI imaging mediated tumor therapy. This strategy provides a new idea for the convenient construction of polymeric drugs for tumor theranostics.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery · Graphene and Nanomaterials Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (69)

Show source-provided references
1. Cancer statistics, 202010.3322/caac.21590 ↗
2. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate10.1158/1078-0432.CCR-04-0789 ↗
3. Mechanism of action of antitumor drugs that interact with microtubules and tubulin10.2174/1568011023354290 ↗
4. Cancer nanomedicine: progress, challenges and opportunities10.1038/nrc.2016.108 ↗
5. Delivering nanomedicine to solid tumors10.1038/nrclinonc.2010.139 ↗
6. Drug-therapy - chemotherapy of lung-cancer10.1056/NEJM199211123272006 ↗
7. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma10.1002/1097-0142(20000901)89:5<1037::AID-CNCR13>3.0.CO;2-Z ↗
8. Liposomal drug delivery systems: from concept to clinical applications10.1016/j.addr.2012.09.037 ↗
9. Design, functionalization strategies and biomedical applications of targeted biodegradable/biocompatible polymer-based nanocarriers for drug delivery10.1039/C2CS35265F ↗
10. Polymer-drug conjugate therapeutics: advances, insights and prospects10.1038/s41573-018-0005-0 ↗
11. Precise nanomedicine for intelligent therapy of cancer10.1007/s11426-018-9397-5 ↗
12. Controlled drug delivery with nanoassemblies of redox-responsive prodrug and polyprodrug amphiphiles10.1016/j.jconrel.2020.07.010 ↗
13. Positively charged polyprodrug amphiphiles with enhanced drug loading and reactive oxygen species-responsive release ability for traceable synergistic therapy10.1021/jacs.8b01641 ↗
14. ROS-responsive polyprodrug nanoparticles for triggered drug delivery and effective cancer therapy10.1002/adma.201700141 ↗
15. Smart and hyper-fast responsive polyprodrug nanoplatform for targeted cancer therapy10.1016/j.biomaterials.2015.10.056 ↗
16. TME-responsive polyprodrug micelles for multistage delivery of doxorubicin with improved cancer therapeutic efficacy in rodents10.1002/adhm.202000387 ↗
17. Polyprodrug amphiphiles: hierarchical assemblies for shape-regulated cellular internalization, trafficking, and drug delivery10.1021/ja409686x ↗
18. Cell-penetrating hyperbranched polyprodrug amphiphiles for synergistic reductive milieu-triggered drug release and enhanced magnetic resonance signals10.1021/ja5105848 ↗
19. Concurrent drug unplugging and permeabilization of polyprodrug-gated crosslinked vesicles for cancer combination chemotherapy10.1002/adma.201706307 ↗
20. Phenol-yne click polymerization: an efficient technique to facilely access regio- and stereoregular poly(vinylene ether ketone)s, chemistry-a10.1002/chem.201702966 ↗
21. Spontaneous amino-yne click polymerization: a powerful tool toward regio- and stereospecific poly(beta-aminoacrylate)s10.1021/jacs.7b00929 ↗
22. Metal-free alkyne polyhydrothiolation: synthesis of functional poly(vinylenesulfide)s with high stereoregularity by regioselective thioclick polymerization10.1002/adfm.200901943 ↗
23. A simple approach to bioconjugation at diverse levels: metal-free click reactions of activated alkynes with native groups of biotargets without prefunctionalization10.1155/2018/3152870 ↗
24. Beta-aminoacrylate synthetic hydrogels: easily accessible and operationally simple biomaterials networks10.1002/anie.201808452 ↗
25. Metal-free click polymerization of propiolates and azides: facile synthesis of functional poly(aroxycarbonyltriazole)s10.1039/c2py00586g ↗
26. Injectable and degradable pH-responsive hydrogels via spontaneous amino-Yne click reaction10.1021/acsami.7b18141 ↗
27. Multicomponent coordination-driven self-assembly of fused C3v polygons10.1021/acs.organomet.0c00604 ↗
28. Interfacial metal coordination in engineered protein and peptide assemblies10.1016/j.cbpa.2013.12.013 ↗
29. Intelligent nanoflowers: a full tumor microenvironment-responsive multimodal cancer theranostic nanoplatform10.1039/C9NR04768A ↗
30. Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications10.1021/cr980440x ↗
31. Nano-sized MRI contrast agents with dendrimer cores10.1016/j.addr.2005.09.016 ↗
32. Coordinatively unsaturated Fe3+ based activatable probes for enhanced MRI and therapy of tumors10.1002/anie.201904880 ↗
33. Targeting ferroptosis to iron out cancer10.1016/j.ccell.2019.04.002 ↗
34. The interaction between ferroptosis and lipid metabolism in cancer10.1038/s41392-020-00216-5 ↗
35. Ferroptosis: past, present and future10.1038/s41419-020-2298-2 ↗
36. Polymer vesicles: modular platforms for cancer theranostics10.1002/adma.201705674 ↗
37. A metal-polyphenol-coordinated nanomedicine for synergistic cascade cancer chemotherapy and chemodynamic therapy10.1002/adma.201906024 ↗
38. Modular assembly of superstructures from polyphenol-functionalized building blocks10.1038/nnano.2016.172 ↗
39. PolyMOF nanoparticles: dual roles of a multivalent polyMOF ligand in size control and surface functionalization10.1002/anie.201910542 ↗
40. Structure of the polymer backbones in polyMOF materials10.1021/jacs.0c04546 ↗
41. Block co-polyMOFs: morphology control of polymer-MOF hybrid materials10.1039/C8SC04250K ↗
42. Peptide-induced super-assembly of biocatalytic metal-organic frameworks for programmed enzyme cascades10.1039/C9SC02021G ↗
43. One-pot synthesis of acid-degradable polyphosphazene prodrugs for efficient tumor chemotherapy10.1039/D0TB01992E ↗
44. Hollow MnO2 as a tumor-microenvironment-responsive biodegradable nano-platform for combination therapy favoring antitumor immune responses10.1038/s41467-017-01050-0 ↗
45. Multifunctional polyphosphazene-coated multi-walled carbon nanotubes for the synergistic treatment of redox-responsive chemotherapy and effective photothermal therapy10.1039/C7PY01485F ↗
46. Stimuli-responsive nano-architecture drug-delivery systems to solid tumor micromilieu: past, present, and future perspectives10.1021/acsnano.8b06104 ↗
47. Stimuli-responsive nanocarriers for drug delivery10.1038/nmat3776 ↗
48. Paramagnetic metal complexes as water proton relaxation agents for NMR imaging: theory and design10.1021/cr00081a003 ↗
49. Polycatechol nanoparticle MRI contrast agents10.1002/smll.201502754 ↗
50. DOTA-branched organic frameworks as giant and potent metal chelators10.1021/jacs.9b09269 ↗
51. Chemodynamic therapy: tumour microenvironment-mediated fenton and fenton-like reactions10.1002/anie.201805664 ↗
52. Chemistry of MRI contrast agents: current challenges and new frontiers10.1021/acs.chemrev.8b00363 ↗
53. Ultrasmall nanoparticles induce ferroptosis in nutrient-deprived cancer cells and suppress tumour growth10.1038/nnano.2016.164 ↗
54. Tumor-targeted cascade nanoreactor based on metal–organic frameworks for synergistic ferroptosis–starvation anticancer therapy10.1021/acsnano.9b07789 ↗
55. Fenton-reaction-acceleratable magnetic nanoparticles for ferroptosis therapy of orthotopic brain tumors10.1021/acsnano.8b06201 ↗
56. Sulforaphane mediates glutathione depletion via polymeric nanoparticles to restore cisplatin chemosensitivity10.1021/acsnano.9b07032 ↗
57. Synthesis of iron nanometallic glasses and their application in cancer therapy by a localized fenton reaction10.1002/anie.201510031 ↗
58. Macromolecular MRI contrast agents: structures, properties and applications10.1016/j.progpolymsci.2012.07.001 ↗
59. Fenton chemistry at aqueous interfaces10.1073/pnas.1314885111 ↗
60. Mechanisms of ferroptosis and relations with regulated cell death: a review10.3389/fphys.2019.00139 ↗
61. Molecular magnetic resonance imaging with Gd(III)-based contrast agents: challenges and key advances10.1021/jacs.9b09149 ↗
62. Gadolinium-based contrast agents for magnetic resonance cancer imaging10.1002/wnan.1198 ↗
63. Ligand design strategies to increase stability of gadolinium-based magnetic resonance imaging contrast agents10.1038/s41467-019-09342-3 ↗
64. Gadolinium-based contrast agent toxicity: a review of known and proposed mechanisms10.1007/s10534-016-9931-7 ↗
65. Gadolinium-based contrast agent accumulation and toxicity: an update10.3174/ajnr.A4615 ↗
66. Mn(II)-based MRI contrast agent candidate for vascular imaging10.1021/acs.jmedchem.0c00197 ↗
67. Manganese-based contrast agents for magnetic resonance imaging of liver tumors: structure-activity relationships and lead candidate evaluation10.1021/acs.jmedchem.8b00964 ↗
68. Exceedingly small iron oxide nanoparticles as positive MRI contrast agents10.1073/pnas.1620145114 ↗
69. Iron(III) contrast agent candidates for MRI: a survey of the structure-effect relationship in the last 15 years of studies10.1002/ejic.201501166 ↗